Patients with diabetes or those on insulin or other glucose-lowering medications should have glucose levels monitored closely when starting or adjusting sermorelin therapy, as dosage adjustments to their diabetes medications may be needed
Long study (12+ weeks) with IGF-1 tracking: Tesamorelin + Ipamorelin
Among patients who qualified under existing indications, 74% had dyslipidemia, 62% had hypertension, 33% had prediabetes, 17% had obstructive sleep apnea, and 11% had cardiovascular disease
Transdermal delivery can be used to bypass the first-pass effect, which would otherwise prematurely metabolize the drugs
Key Safety Features Does not significantly elevate cortisol, prolactin, or aldosterone at standard doses the defining advantage over other GHRPs [1]